Trials / Completed
CompletedNCT00685815
Intravenous Iron Metabolism in Restless Legs Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- American Regent, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome
Detailed description
To determine the effects of high-dose infusions of iron on Restless Legs Syndrome (RLS) symptoms and brain concentrations of iron.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferric Carboxymaltose (FCM) | 500mg FCM in 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4 |
| DRUG | Placebo | 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4 |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2010-12-01
- Completion
- 2012-12-01
- First posted
- 2008-05-28
- Last updated
- 2025-05-06
- Results posted
- 2025-05-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00685815. Inclusion in this directory is not an endorsement.